Century Therapeutics 2025 Q1 Earnings Surges to Profitability with 372.8% Net Income Increase

Century Therapeutics (IPSC) reported its fiscal 2025 Q1 earnings on Nov 14, 2025, marking a dramatic turnaround in profitability. The company’s results far exceeded expectations, with a record net income and a 12,667.7% revenue surge. Analysts highlight the strategic shift toward high-potential programs and cost optimization as key drivers of this performance.

Revenue

Total revenue skyrocketed to $109.16 million in 2025 Q1, up from $855,000 in 2024 Q1, driven entirely by collaboration revenue. This segment accounted for the entire $109.16 million, reflecting a one-time windfall from the termination of a partnership.

Earnings/Net Income

Century Therapeutics returned to profitability with EPS of $0.89 in 2025 Q1, reversing a $0.45 loss in 2024 Q1. Net income surged to $76.56 million, a 372.8% improvement from a $28.06 million loss. This marked a historic high for Q1 net income in four years, underscoring the company’s operational resilience.

Post-Earnings Price Action Review

The strategy of buying IPSC shares on revenue-raise announcement dates and holding for 30 days showed mixed performance over three years. While the cumulative return was -14.5%, with significant losses in the immediate month post-announcement, longer-term recovery suggested some value retention. However, the NASDAQ Composite outperformed IPSC by 18% during the same period, highlighting the stock’s volatility and suboptimal short-term returns.

Additional News

1. Type 1 Diabetes Program Launch: Century announced CNTY-813, an Allo-Evasion™ 5.0-engineered iPSC beta islet therapy, with IND-enabling studies set for late 2025 and an IND submission in 2026. Preclinical data demonstrated rapid diabetes reversal and sustained glucose control.

2. Q3 2025 Net Loss Widens: Despite lower R&D and G&A expenses, the company posted a $34.4 million net loss for Q3, driven by flat revenue and ongoing clinical development costs. Cash reserves, however, remain sufficient for operations through 4Q 2027.

3. Clinical Trial Adjustments: Century discontinued its CALiPSO-1 trial for CNTY-101 to prioritize investigator-led studies, while CNTY-308 advances toward clinical trials in 2026. These moves reflect a focus on high-impact programs and cost efficiency.

CEO Commentary

Not available due to missing transcript data.

Guidance

No forward-looking guidance provided in the available data.